TABLE 3.
Cox regression for overall survival
| Univariate analysis | Multivariable analysis A: number of POCs | Multivariable analysis B: grade of POCs | Multivariable analysis C: cardiopulmonary POCs | Multivariable analysis D: thromboembolic POCs | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | p Value | HR (95% CI) | p Value | HR (95% CI) | p Value | HR (95% CI) | p Value | HR (95% CI) | p Value | |
| Age | 1.02 (1.01–1.04) | < 0.01 | 1.02 (1.01–1.03) | < 0.01 | 1.02 (1.01–1.03) | 0.02 | 1.02 (1.00–1.03) | 0.03 | 1.02 (1.00–1.03) | 0.04 |
| BMI | 0.99 (0.97–1.02) | 0.68 | – | – | – | – | – | – | – | – |
| Number of comorbidities | ||||||||||
| 0 | Reference | Reference | Reference | Reference | Reference | |||||
| 1 | 1.48 (0.91–2.41) | 0.11 | 1.34 (0.81–2.22) | 0.26 | 1.18 (0.69–1.98) | 0.54 | 1.22 (0.73–2.03) | 0.45 | 1.26 (0.75–2.10) | 0.38 |
| 2 | 1.62 (0.93–2.81) | 0.08 | 1.78 (1.03–3.07) | 0.04 | 1.59 (0.91–2.79) | 0.10 | 1.57 (0.91–2.72) | 0.11 | 1.61 (0.93–2.79) | 0.09 |
| 3 | 1.65 (0.78–3.51) | 0.19 | 1.49 (0.72–3.07) | 0.28 | 1.55 (0.73–3.27) | 0.25 | 1.58 (0.75–3.33) | 0.23 | 1.54 (0.73–3.24) | 0.25 |
| ≥ 4 | 2.23 (1.11–4.49) | 0.03 | 2.29 (1.07–4.89) | 0.03 | 2.29 (1.06–4.93) | 0.04 | 2.02 (0.95–4.33) | 0.07 | 2.12 (0.99–4.53) | 0.05 |
| NAC | 2.14 (1.46–3.14) | < 0.01 | 2.50 (1.57–3.98) | < 0.01 | 2.24 (1.37–3.67) | < 0.01 | 2.20 (1.36–3.55) | < 0.01 | 2.31 (1.43–3.72) | < 0.01 |
| Neoadjuvant CRT | 1.56 (1.04–2.33) | 0.03 | 1.24 (0.79–1.94) | 0.35 | 1.48 (0.91–2.41) | 0.11 | 1.56 (0.97–2.51) | 0.07 | 1.48 (0.92–2.39) | 0.11 |
| Tumor differentiation | ||||||||||
| Well | Reference | |||||||||
| Moderate | 3.25 (0.80–13.21) | 0.09 | – | – | – | – | – | – | – | – |
| Poor | 8.12 (1.88–34.97) | 0.01 | – | – | – | – | – | – | – | – |
| Undifferentiation | 5.74 (0.52–65.5) | 0.15 | – | – | – | – | – | – | – | – |
| Pathologic stage (AJCC 8th edition) | ||||||||||
| I | Reference | Reference | Reference | Reference | Reference | |||||
| II | 1.43 (0.89–2.28) | 0.13 | 1.41 (0.85–2.34) | 0.11 | 1.44 (0.85–2.41) | 0.17 | 1.40 (0.84–2.33) | 0.20 | 1.47 (0.88–2.45) | 0.14 |
| III | 2.32 (1.56–3.45) | < 0.01 | 2.41 (1.57–3.71) | < 0.01 | 2.25 (1.46–3.49) | < 0.01 | 2.22 (1.44–3.42) | < 0.01 | 2.35 (1.52–3.64) | < 0.01 |
| Number of POCs | ||||||||||
| No POCs | Reference | Reference | ||||||||
| Single | 1.07 (0.82–1.40) | 0.63 | 0.74 (0.47–1.17) | 0.20 | ||||||
| Multiple | 1.52 (1.18–1.97) | < 0.01 | 1.57 (1.02–2.40) | 0.03 | ||||||
| Grade of POCs | ||||||||||
| No POCs | Reference | – | – | Reference | – | – | – | – | ||
| Minor POCs | 1.01 (0.67–1.49) | 0.95 | – | – | 0.80 (0.51–1.25) | 0.65 | – | – | – | – |
| Major POCs | 2.05 (1.39–3.03) | < 0.01 | – | – | 1.62 (1.04–2.54) | 0.03 | – | – | – | – |
| Type of POCs | – | – | ||||||||
| No POCs | Reference | – | – | – | – | Reference | – | – | ||
| Non-cardiopulmonary POCs | 1.45 (1.02–2.05) | 0.04 | – | – | – | – | 1.02 (0.69–1.49) | 0.93 | – | – |
| Cardiopulmonary POCs | 1.23 (0.73–2.05) | 0.44 | – | – | – | – | 2.78 (1.01–7.88) | 0.05 | – | – |
| Type of POCs | – | – | – | – | ||||||
| No POCs | Reference | – | – | – | – | – | – | Reference | ||
| Non-thromboembolic POCs | 1.24 (0.88–1.73) | 0.22 | – | – | – | – | – | – | 0.97 (0.66–1.43) | 0.87 |
| Thromboembolic POCs | 2.31 (1.24–4.31) | 0.01 | – | – | – | – | – | – | 16.6 (6.37–43.4) | < 0.01 |
| Recurrence | 3.82 (2.79–5.24) | < 0.01 | – | – | – | – | – | – | – | – |
Bold data indicates statistical significance
HR hazard ratio, CI confidence interval, NAC neoadjuvant chemotherapy, CRT chemoradiotherapy, POCs postoperative complications, BMI body mass index, AJCC American Joint Committee on Cancer Multivariable analyses were omitted from the table for infectious, renal, and intestinal dysmotility type of POCs